Company Overview and News

 
Trade war threatens reign of luxury stocks

2018-08-10 theedgemarkets
LONDON/PARIS (Aug 10): An escalating trade war between the United States and China could abruptly end a glittering stock market run for luxury goods firms, with some investors already put off by lofty valuations in a sector powered by shoppers in the two countries.
BOSSY RCO REMYY HUGPF REMYF

 
Trade war threatens reign of luxury stocks

2018-08-10 channelnewsasia
An escalating trade war between the United States and China could abruptly end a glittering stock market run for luxury goods firms, with some investors already put off by lofty valuations in a sector powered by shoppers in the two countries.
BOSSY RCO REMYY HUGPF REMYF

 
Trade war threatens reign of luxury stocks

2018-08-10 reuters
LONDON/PARIS (Reuters) - An escalating trade war between the United States and China could abruptly end a glittering stock market run for luxury goods firms, with some investors already put off by lofty valuations in a sector powered by shoppers in the two countries.
BOSSY RCO REMYY HUGPF REMYF

48
Castle Brands: Performance Remains Solid, Valuation Remains A Question Mark

2018-06-19 seekingalpha - 1
Castle Brands posted a nice FY18, as growth in the core whiskey and ginger beer categories continues.
STZ.B VGR RCO REMYY STZ ROX REMYF

 
REFILE-UPDATE 1-Banks push European bourses higher as ECB speculation lifts yields

2018-06-07 reuters
LONDON, June 7 (Reuters) - European shares switched to risk-on mode on Thursday, joining an overnight rally on Wall Street and in Asia, with the banking sector posting the best performance amid expectations that the European Central Bank may soon start to wind down its stimulus.
RCO REMYY BNNCY REMYF

 
Banks push European bourses higher as ECB speculation lift yields

2018-06-07 thehindubusinessline
European shares switched to risk-on mode on Thursday, joining an overnight rally on Wall Street and in Asia, with the banking sector posting the best performance amid expectations that the European Central Bank may soon start to wind down its stimulus.
RCO REMYY BNNCY REMYF

 
Banks push European bourses higher as ECB speculation lift yields

2018-06-07 reuters
LONDON, June 7 (Reuters) - European shares switched to risk-on mode on Thursday, joining an overnight rally on Wall Street and in Asia, with the banking sector posting the best performance amid expectations that the European Central Bank may soon start to wind down its stimulus.
RCO REMYY REMYF

1
Carlsberg Loses Market Share in Russia on Beer Turmoil - Bloomberg

2018-05-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
RCO REMYY RI REMYF

1
GRAPHIC-Euro's boom spells corporate gloom for region's exporters

2018-05-01 reuters
LONDON (Reuters) - A strong euro has helped U.S. companies extend their sales outperformance over Europe to multi-year highs in the first quarter, according to Reuters data - though experts expect the trend to begin to reverse later this year.
RCO REMYY RI REMYF

27
Tipsy Profits: Whiskey & Spirits ETF

2018-04-06 seekingalpha
Welcome to the first ETF to provide diversified exposure to the global whiskey and spirits industry.
532432 TWMJF BF.B DGEAF WEED UNITDSPR UQNTY MGPI RCO REMYY RI REMYF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:RCO / REMY COINTREAU on message board site Silicon Investor.

American Superconductor (AMSC) American Superconductor (AMSC) American Superconductor (AMSC) IntercontinentalExchange ICE IntercontinentalExchange ICE IntercontinentalExchange ICE
UTStarcom Inc. (UTSI) UTStarcom Inc. (UTSI) UTStarcom Inc. (UTSI) San Marco (SMN.V) Samples 8.46 g/t Gold; 43.0 g/t Silver; 1. San Marco (SMN.V) Samples 8.46 g/t Gold; 43.0 g/t Silver; 1. San Marco (SMN.V) Samples 8.46 g/t Gold; 43.0 g/t Silver; 1.
ROMARCO MINERALS - R : TSE ROMARCO MINERALS - R : TSE ROMARCO MINERALS - R : TSE Silvercorp Metals Inc. Silvercorp Metals Inc. Silvercorp Metals Inc.
Pen Intercom (PENC) - Ready to fly? Pen Intercom (PENC) - Ready to fly? Pen Intercom (PENC) - Ready to fly? New reconfigurable supercomputer that fits on your desktop New reconfigurable supercomputer that fits on your desktop New reconfigurable supercomputer that fits on your desktop
HURC Hurco coming on strong HURC Hurco coming on strong HURC Hurco coming on strong Conductus (NASDAQ: CDTS) superconductors Conductus (NASDAQ: CDTS) superconductors Conductus (NASDAQ: CDTS) superconductors